Sort
50,496 grants matching “lung cancer”
Multidisciplinary Collaborative Clinical Research, Core Facilities and Other Clinical Services in NIDDK Program Area Diseases
$914,364James Balow · National Institute Of Diabetes And Digestive And Kidney Diseases · ZID · FY2017 · DK
Tissue factor-dependent coagulation in thrombosis and immune responses
$914,340Nigel Mackman · Univ Of North Carolina Chapel Hill · R35 · FY2024 · HL
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer
$914,249Worapol Ngamcherdtrakul · Pdx Pharmaceuticals, Inc. · R44 · FY2024 · CA
Genomics and Proteomics of Head and Neck Cancer
$914,150Carter Van Waes · National Institute On Deafness And Other Communication Disorders · ZIA · FY2021 · DC
Ceramides as novel drivers of metabolic dysfunction and colorectal cancer
$913,866Mary Christine Playdon · University Of Utah · U01 · FY2022 · CA
Yoga for women with breast cancer undergoing radiotherapy
$913,742Lorenzo Cohen · University Of Tx Md Anderson Can Ctr · R01 · FY2010 · CA
The Boston University - UCLA Lung Cancer Biomarker Characterization Center
$913,695Marc Elliott Lenburg · Boston University Medical Campus · U2C · FY2024 · CA
Novel mechanisms regulating immunity to respiratory virus infection
$913,500Silke Paust · Jackson Laboratory · R01 · FY2023 · AI
Incorporating Phase I/II drug/chemical metabolism in HTS via micro scale co-culture
$913,343Jose Antonio Jimenez-Torres · Onexio Biosystems, Llc · R44 · FY2020 · ES
Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies
$913,132Julien Sage · Stanford University · R35 · FY2024 · CA
Determining the Fate of Transmembrane Proteins
$913,002Allan M Weissman · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
PLCO Trial Etiologic and Early Marker Study
$912,943Richard S Hayes · Cancer Epidemiology And Genetics · Z01 · FY2007 · CA
Mechanisms of Clathrin-Independent Endocytosis
$912,767Julie G. Donaldson · National Heart, Lung, And Blood Institute · ZIA · FY2017 · HL
A NOVEL IMMUNE MODULATING ANTIBODY FOR THE TREATMENT OF LUNG CANCER
$912,212Duke University · · FY2019 · Defense Health Agency
Infections, immunity, and inflammation in cancer
$911,869Eric A Engels · Division Of Cancer Epidemiology And Genetics · ZIA · FY2011 · CA
PREVENT EFFICACY POOL: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM
$911,531Chinthalapally Rao · University Of Oklahoma Hlth Sciences Ctr · N01 · FY2021 · CA
Cytokine Gene Therapy of Cancer - Preclinical Studies
$911,332University Of Pittsburgh At Pittsburgh · P01 · FY2005 · CA
iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium
$911,328Powel H Brown · University Of Tx Md Anderson Can Ctr · UG1 · FY2022 · CA
NRF Transcription Factors in Environmental Stress and Disease Intervention
$911,114Donna D Zhang · University Of Arizona · R35 · FY2022 · ES
Validation of Biomarkers of Risk for the Early Detection of Lung Cancer
$910,582Pierre P Massion · Vanderbilt University Medical Center · U01 · FY2019 · CA
Regulation and Function of WIP1 Phosphatase and its Role in Tumor Cells
$910,513Ettore Appella · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Pathomic Predictors of Prostate Cancer Progression
$910,446Parag Kumar Mallick · Stanford University · R01 · FY2020 · CA
Consultation and Collaboration
$910,442Barry Graubard · Division Of Cancer Epidemiology And Genetics · ZIA · FY2017 · CA
Clinical Cancer Cytogenetics
$910,395Diane C Arthur · Division Of Basic Sciences - Nci · ZID · FY2015 · CA
Diazeniumdiolates as Broad-Spectrum Anticancer Agents
$909,984Larry K Keefer · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA